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Abstract: Pituitary tumor apoplexy (PTA) classically comprises sudden-onset headache, loss of vision,
ophthalmoparesis, and decreased consciousness. It typically results from hemorrhage and/or infarction
within a pituitary adenoma. Presentation is heterologous, and optimal management is debated. The
time course of recovery of cranial nerve deficits (CNDs) and headaches is not well established. In this
study, a retrospective series of consecutive patients with PTA managed at a single academic institution
over a 22-year period is presented. Headaches at the time of surgery were more severe in the early and
subacute surgical cohort and improved significantly within 72 h postoperatively (p < 0.01). At one year,
90% of CNDs affecting cranial nerves (CNs) 3, 4, and 6 had recovered, with no differences between
early (<4 d), subacute (4–14 d), and delayed (>14 d) time-to-surgery cohorts. Remarkably, half recovered
within three days. In total, 56% of CN2 deficits recovered, with the early surgery cohort including more
severe deficits and recovering at a lower rate (p = 0.01). No correlation of time-to-surgery and rapidity of
recovery of CNDs was observed (p = 0.65, 0.72). Surgery for PTA is associated with rapid recovery of
CNDs in the early, subacute, and delayed time frames, and with rapid headache improvement in the
early and subacute time frames in 50% or more of patients.
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1. Introduction

published maps and institutional affil-

Pituitary tumor apoplexy (PTA) is a rare syndrome classically including sudden-onset
headache, partial or complete loss of vision, ophthalmoparesis, and a decreased level of consciousness. It is thought to result from infarction and/or hemorrhage within a pituitary tumor.
This causes the rapid expansion of sellar contents and the compression of adjacent structures,
including optic nerves, optic chiasm, and intracavernous sinus cranial nerves (CNs) (e.g., 3/III,
4/IV, V1, V2, 6/VI), ultimately leading to cranial nerve deficits (CNDs) [1–3]. The pathogenesis
of headache in PTA may involve pain fibers traveling within the sellar meninges and appears
to correlate with increased intrasellar pressure (ISP) [4–7]. PTA was first described in a case
series in 1950 of five patients who suffered severe symptoms, including blindness and death [8].
Subsequent studies proposed that early surgery to decompress the sella turcica and resect the
tumor might improve patient outcomes and established a treatment paradigm for early surgery
in this condition [9–11]. However, the definition of this condition has changed in the era of
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modern, high-resolution, and widely accessible magnetic resonance (MR) and computed tomography (CT) imaging, which can detect small and often subclinical hemorrhages within pituitary
tumors [12–15]. With a wide spectrum of clinical severity evident in patients suffering from
apparently similar pathophysiologic processes [16], controversy exists as to optimal treatment.
For patients with visual symptoms (deficit of CN 2), most centers and guidelines continue to
recommend prompt surgical decompression to preserve or improve visual function, although
the timing of surgery is not well-defined [17]. The pituitary apoplexy score was proposed in
2011 to help guide management but does not include headache as a factor [18].
We performed a retrospective analysis of all patients who underwent surgery for PTA
at a single institution in a 22-year period to ask if time-to-surgery correlates with more
rapid resolution of headaches or CNDs.
2. Methods
2.1. Record Collection
Records of consecutive patients who underwent surgery for PTA at a single center
between the years 2001 and 2022 were retrospectively reviewed. This study was approved
by the Institutional Review Board of Washington University School of Medicine in St. Louis.
Inclusion criteria included acute-onset headache in patients with radiologic evidence of
hemorrhage or infarction within a pituitary tumor and pathology consistent with hemorrhage and/or necrosis within the adenoma. Patients without CNDs were also included.
Details of the history of present illness, radiologic studies, surgical management, and
follow-up were gathered via retrospective chart review. In six cases, the patient presented
more than 60 days after ictus. For these patients, the duration of symptoms was censored at
60 days for subsequent analysis. Visual acuity, visual fields, and ocular motility data were
obtained from combined records of ophthalmologists, neurosurgeons, and neurologists.
Maximal tumor diameter was determined by preoperative imaging. MRI images were used
when available, and CT images were used otherwise. Headache severity was obtained
from nursing shift reports recorded at 0700 and 1900 daily in the electronic medical record
and was marked categorically as “absent”, “mild,” “severe”, or “unable to obtain” based
on the patient’s response. Headache data were gathered 72 h pre- and postoperatively prior
to statistical analysis.
2.2. Statistical Analyses
Baseline characteristics of patients were compared using Pearson’s χ2 test or analysis of variance (ANOVA) for categorical or continuous variables, respectively. Pre- and
postoperative headache scores were analyzed in two ways. Scores were first compiled and
analyzed using Pearson’s χ2 test. Categorical headache responses were then converted to
numerical scales using the following scores: Absent-1, Mild-2, and Severe-3. Scores were
averaged in the pre- and postoperative period by each study subject and compared using
the Wilcoxon matched pairs signed rank test. For CND improvement and resolution curves,
Kaplan–Meier survival estimates were constructed. Survival curves were compared using
the log-rank test, with significance set at p < 0.05. Cox proportional hazards regression
analysis was used for multivariate analysis.
3. Results
3.1. Baseline Characteristics
Baseline characteristics of patients are presented in Table 1. In total, 59 patients were
identified within the study period (40 male, 19 female). The median age at presentation was
54 years (a range of 17–94 years). The median follow-up time was 60 days (interquartile
range 23–242 days). In total, 8 of 59 (13%) patients presented with a known history of
pituitary neoplasm.
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Table 1. Baseline Characteristics of Study Patients.

Number of Patients (%)
Headaches
Radiologic Hemorrhage
Hemorrhage or Necrosis
Mean Time to Surgery (d)
Mean Tumor Diameter (mm)
Cranial Nerve Deficits
Blindness, Uni or Bilateral
Endoscopic Endonasal
Sublabial

Total

Operative Timeframe Cohort
Early (<=72 h)
Subacute (4 d–14 d)

Delayed (>14d)

59 (100)
59 (100)
59 (100)
59 (100)
17.6
24.9
46 (78)
5 (8)
56 (95)
3 (5)

13 (22)
13 (100)
13 (100)
13 (100)
1.9
32.3
11 (85)
3 (23)
12 (92)
1 (8)

19 (32)
19 (100)
19 (100)
19 (100)
40.4
22.7
13 (68)
0 (0)
19 (100)
0 (0)

27 (45)
27 (100)
27 (100)
27 (100)
9.0
22.9
22 (81)
2 (7)
25 (93)
2 (7)

p Value
<0.01
<0.01
0.46
0.06
0.47

Preoperative characteristics of patients. Categorical variables were compared using Pearson’s χ2 test. Continuous
variables were compared using ANOVA. Statistical significance set at p < 0.05.

The mean duration from symptom onset to surgery was 17 days, with a median of
11 days (interquartile range, 3–14 days). The early surgery cohort was defined as having
undergone surgery <4 days after ictus, while the subacute and delayed cohorts underwent
surgery between 4–14 days and >14 days, respectively. There was a higher proportion of
male patients in the early and subacute treatment groups than in the delayed treatment
group (p = 0.02). The mean maximal tumor diameter as measured by preoperative imaging
was 2.5 cm within the entire study and was significantly greater in the early cohort (3.2 cm)
than in the subacute (2.3 cm) and delayed cohorts (2.3 cm) (p = 0.02).
3.2. Headache Presentation and Resolution
Headache data are displayed in Figure 1. All patients included in this study presented
with headaches. Pre- and postoperative headache scores were available in 46 (77%) of
59 patients. In patients with available pre- and postoperative data, 11 (23%) headaches
resolved before the 24 h period immediately preoperatively (three subacute, eight delayed). Within the early and subacute cohorts, the severity of headaches significantly
decreased within 72 h following surgery (p < 0.01). Within the delayed surgical cohort,
the distribution of headaches was not different between pre-and postoperative evaluation.
Severe headaches in the immediate preoperative period were significantly more common
in the early and subacute cohorts as compared to the delayed cohort (p <0.01). Among
all postoperative patients, those within the delayed cohort reported severe headaches at a
significantly higher rate (p < 0.01).
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Figure1.1. PrePre- and
and Postoperative
Postoperative Headaches.
Figure
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3.3. Clinical Presentation of Cranial Nerve Deficits
3.3. Clinical Presentation of Cranial Nerve Deficits
Baseline cranial nerve data are presented in Table 2. In total, 46 patients (78%) preBaseline cranial nerve data are presented in Table 2. In total, 46 patients (78%) presented with at least one CN deficit. A total of 81 CNDs were detected, for an average of
sented with at least one CN deficit. A total of 81 CNDs were detected, for an average
1.3 per patient. Twenty-two (37%) patients presented with a CN2 deficit (7 unilateral, 15
of 1.3 per patient. Twenty-two (37%) patients presented with a CN2 deficit (7 unilateral,
bilateral), including partial or complete reduction in visual acuity or visual field. Five pa15
bilateral),
including
or complete
visual acuity
or visual
field.
tients
experienced
total partial
blindness
in at leastreduction
one eye byinpresentation
(four
bilateral,
oneFive
patients
experienced
at leastwere
one eye
by presentation
(four blindness.
bilateral, one
unilateral).
Therefore,total
24%blindness
of all CN2indeficits
associated
with complete
unilateral).
Therefore,
24%
of
all
CN2
deficits
were
associated
with
complete
blindness.
The average time to presentation for patients with at least unilateral blindness was twoThe
average
timeoftothese
presentation
patients with
at leastvisual
unilateral
blindness
was
twothe
days.
days. Some
patients for
experienced
progressive
loss to
blindness
over
Some
of
these
patients
experienced
progressive
visual
loss
to
blindness
over
the
course
course of many hours prior to presentation, which delayed their presentations. Three of of
many
hours prior
to least
presentation,
delayed
their presentations.
ofsymptom
five patients
five patients
with at
unilateralwhich
blindness
underwent
surgery withinThree
72 h of
with
at
least
unilateral
blindness
underwent
surgery
within
72
h
of
symptom
onset. The remaining two patients fell into the subacute cohort. In total, 26 patientsonset.
(44%)The
remaining
two
patients
fell
into
the
subacute
cohort.
In
total,
26
patients
(44%)
presented
presented with a CN 3 deficit. Twelve patients (20%) presented with a CN 6 deficit. Only
with
a CN
3 deficit.
patients
(20%)
presented
withinaboth
CN visual
6 deficit.
Only
one
CN 4
one CN
4 deficit
wasTwelve
noted. Ten
patients
(16%)
had deficits
acuity
and
ocudeficit
was noted. Ten patients (16%) had deficits in both visual acuity and ocular motility.
lar motility.
Table2.2.Cranial
Cranial Nerve
Nerve Deficits
Deficits at
Table
at Presentation.
Presentation.

Cranial
Cranial Nerve
Nerve
II
II
III
III
VI
VI

Unilateral
Unilateral
7
7
26 26
13 13

Bilateral
Bilateral
15
15
0
0
1
1

p Valuep Value
<0.01 <0.01

In total, 46 patients (78%) presented with a cranial nerve deficit. CN2 deficits were frequently bilateral, while
deficits affecting CNs 3, 4, and 6 were almost entirely unilateral (p < 0.01).
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In total, 46 patients (78%) presented with a cranial nerve deficit. CN2 deficits were frequently bilateral, while deficits affecting CNs 3, 4, and 6 were almost entirely unilateral (p < 0.01).

3.4. Resolution and Improvement in Cranial Nerve Impairments
3.4. Resolution
and Improvement
Unlike with
headaches, in
noCranial
CNDsNerve
wereImpairments
observed to resolve spontaneously prior to
Unlike
withthis
headaches,
no CNDs CN
wererecoveries
observed to
spontaneously
to
surgery
within
study’s timeline.
areresolve
displayed
in Figure 2.prior
At one-year
surgery
within
this
study’s
timeline.
CN
recoveries
are
displayed
in
Figure
2.
At
one-year
follow-up, 72% of CNDs were completely resolved, with an additional 16% improved
follow-up,
72%
of CNDs Deficits
were completely
an additional
16% improved
without
full
resolution.
of CNs 3,resolved,
4, and 6 with
improved
more frequently
than visual
without
full
resolution.
Deficits
of
CNs
3,
4,
and
6
improved
more
frequently
visual
deficits: 56% of CN 2 deficits resolved in one year versus 90% of CN 3, than
4, and
6 deficits
deficits:
56%
of severity
CN 2 deficits
resolved
in one
year
90%
of CN 3, 4,among
and 6 deficits
(p
= 0.02).
The
of visual
deficits
was
notversus
evenly
distributed
cohorts.(pSevere
= 0.02).deficits
The severity
visualtrended
deficits was
not evenly
among cohorts.(p
Severe
visual
in ourofseries
towards
earlierdistributed
surgical decompression
= 0.06). By
visual deficits in our series trended towards earlier surgical decompression (p = 0.06). By
Cox Proportional Hazards multivariate analysis, this subset of patients was identified as
Cox Proportional Hazards multivariate analysis, this subset of patients was identified as
having reduced rates of CN 2 resolution (p = 0.03). Among CN 2 deficits, 10% within the
having reduced rates of CN 2 resolution (p = 0.03). Among CN 2 deficits, 10% within the
early surgery cohort resolved completely compared to 75% in each of the subacute and
early surgery cohort resolved completely compared to 75% in each of the subacute and
delayed cohorts (p = 0.01). Among early, subacute, and delayed cohorts, there were no
delayed cohorts (p = 0.01). Among early, subacute, and delayed cohorts, there were no
significant
differencesininthe
the
resolution
of CN
oculomotor
deficits
at year.
one year.
significant differences
resolution
of CN
oculomotor
deficits
at one

Figure 2. Postoperative Resolution and Improvement of Cranial Nerve Deficits. (A)—Postoperative
Improvement and Resolution of CNDs. (B)—Resolution of CN2 vs CNs 3, 4, and 6. (C)—Resolution
of CN2 by time-to-surgery cohort. (D)—Resolution of CNs 3, 4, and 6 by time-to-surgery cohort.
(E)—Improvement in CN2 by time-to-surgery cohort. (F)—Improvement in CNs 3, 4, and 6 by
time-to-surgery cohort.

Improvement and Resolution of CNDs. (B)—Resolution of CN2 vs CNs 3, 4, and 6. (C)—Resolution
of CN2 by time-to-surgery cohort. (D)—Resolution of CNs 3, 4, and 6 by time-to-surgery cohort.
(E)—Improvement in CN2 by time-to-surgery cohort. (F)—Improvement in CNs 3, 4, and 6 by timeto-surgery cohort.
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In regression analysis of patients with CNDs that eventually recovered, time to surgery was not correlatedInwith
the rapidity
postoperative
recovery
for
either time
CN2toor
CNs
regression
analysis ofof
patients
with CNDs that
eventually
recovered,
surgery
3, 4, and 6 (Figure 3).
14 ofwith
28the
(50%)
of of
CNs
3, 4, andrecovery
6 deficits
recovered
within
wasIn
nottotal,
correlated
rapidity
postoperative
for either
CN2 or CNs
3, 4,
and
6
(Figure
3).
In
total,
14
of
28
(50%)
of
CNs
3,
4,
and
6
deficits
recovered
within
the first three days postoperatively. Within seven days, 50% of CN2 and 55% of CNs 3,the4,
first three days postoperatively. Within seven days, 50% of CN2 and 55% of CNs 3, 4, and
and 6 deficits had resolved.
Recovery within three days was observed in patients under6 deficits had resolved. Recovery within three days was observed in patients undergoing
going surgery 40 and
60 days
after
ictus.
surgery
40 and
60 days
after ictus.

Figure 3. Correlation of Time to Surgery and Rapidity of Postoperative Recovery. Linear regression

Figure 3. Correlation of Time to Surgery and Rapidity of Postoperative Recovery. Linear regression
analysis and F-Test as performed to assess correlation in (A)—CNs 3, 4, and 6, and (B)—CN2.
analysis and F-Test as performed to assess correlation in (A)—CNs 3, 4, and 6, and (B)—CN2.
3.5. Complications
Complications are visualized in Table 3 and included intraoperative postoperative DVT,
postoperative diabetes insipidus (DI), postoperative heparin-induced thrombocytopenia (HIT),
healthcare-associated
pneumonia
(HCAP),
cerebrospinal fluid
leak requiring
Complications postoperative
are visualized
in Table 3 and
included
intraoperative
postoperative
the placement of a lumbar drain, and death during hospitalization. In the latter case, the
DVT, postoperative diabetes insipidus (DI), postoperative heparin-induced thrombocypatient was an 86-year-old woman whose death resulted from complications from HIT. There
topenia (HIT), postoperative
healthcare-associated
pneumonia
(HCAP),
cerebrospinal
were no statistically
significant differences between
cohorts with
regard to complications.

3.5. Complications

fluid leak requiring the placement of a lumbar drain, and death during hospitalization. In
Table 3. Complications.
the latter case, the patient
was an 86-year-old woman whose death resulted from complications from HIT. There were noOperative
statistically
significant
differences between cohorts with
Timeframe
Cohort
Total
p Value
Early (<=72 h)
Subacute (4 d–14 d)
Delayed (>14 d)
regard to complications.
Deep Vein Thrombosis
2 (3)
0 (0)
2 (7)
Diabetes Insipidus
5 (8)
1 (7)
3 (11)
Table
3. Complications.
Heparin
Induced
1 (2)
1 (7)
0 (0)
Thrombocytopenia
Pneumonia
1 (2)
0 (0)
Total
Operative
Timeframe
Cohort 1 (3)
Cerebrospinal Fluid Leak
10 (17)
2 (15)
5 (19)
d)
Death During HospitalizationEarly
1 (2)(<=72 h)1 (7)Subacute (4 d–14
0 (0)

hrombosis
2 (3)
nsipidus
5 (8)
hrombocytopenia1 (2)
onia
1 (2)
Fluid Leak
10 (17)
ospitalization
1 (2)

0 (0)
1 (5)

0.29
0.78

0 (0)

0.17

0 (0)
3 (16)
(>14
0 (0) d)

0.55
p Value
0.96

Delayed
0.17
test for differences between cohorts.
0Pearson’s
(0) χ2 test was used2 to(7)
0 (0)
0.29
14.(7)
3 (11)
1 (5)
0.78
Discussion
1 (7) The long-term 0neuro-ophthalmologic
(0)
0 (0)
0.17tumor
and endocrine
outcomes of pituitary
have been1 reviewed
in the literature [19,20],
recovery
0apoplexy
(0)
(3)
0 (0) but the time-course of
0.55
of CNDs and headache improvement has not yet been reported with this level of
2granularity,
(15)
5 (19)
3 (16)
0.96
which is included in the analysis of time to surgery on outcomes.
1 (7) Our observed rates
0 (0)of the long-term recovery 0of(0)
0.17
CNDs mirror the estimations
of several

previous
series
[21–25].
However,
whereascohorts.
some have reported improved visual recovery
Pearson’s χ2 test was used
to test
for
differences
between

4. Discussion
The long-term neuro-ophthalmologic and endocrine outcomes of pituitary tumor ap-
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with early surgery [26–28], this association was not reflected in our data. It is possible that
early surgery could have exacerbated vision loss in this cohort, but we propose instead that
early surgical patients presented with more severe vision loss that resolved at a lower rate,
as multivariate analysis confirmed blindness to be independently associated with persistent
deficit. One-year outcomes were excellent for the recovery of CNDs of 3, 4, and 6, at 90%.
Surgery was frequently associated with rapid recovery of these, with half of all CNDs affecting
ocular movement resolving in the first 3 days after surgery. No difference in the rapidity of
postoperative recoveries was detected between time-to-surgery cohorts, with several rapid
CND recoveries also observed in the delayed treatment cohort. This raises the possibility that,
in certain cases, surgery may expedite CND recovery even at delayed time points, though
future prospective studies will be needed to test this hypothesis more rigorously.
PTA also causes debilitating headaches, the natural history and optimal treatment for
which remain unclear. In a cohort of 44 patients treated with surgery, Zaidi et al. found
headaches resolved at an average of 1.9 weeks postoperatively, and that all headaches
resolved at the latest follow-up [29]. In the present study, we find patients who undergo
surgery earlier have more severe headaches immediately before surgery, and that these
are significantly improved within 72 h postoperatively. By contrast, most patients within
the delayed surgical cohort (all of whom had previously experienced severe and sudden
onset headaches) reported less severe, or absent, headaches by the time of surgery. Delayed
surgical patients experienced no significant change overall in headache distribution after
surgery. Hayashi and colleagues proposed that surgery could relieve headaches by reducing
intrasellar pressure and showed improvement on a standardized headache score in PTA
patients who underwent surgery. However, their postoperative assessment occurred
three months after surgery. The data within the present study support that headache
improvement can occur even within 72 h in the postoperative period.
One limitation of this study is its retrospective nature and inability to mitigate bias
between sub-populations, though multivariate regression analysis helps to account for these.
In future studies, propensity score matching could also potentially provide additional comparative strength between cohorts, though, in this study, discrepancies between calculated
propensity scores of cohorts did not allow for close matching. This data set also reflects the
practice of a single tertiary referral center and will be improved with a multi-institutional
study. Finally, the headache data presented within are based on patients’ subjective responses
to verbal nursing prompts. These data could potentially be improved with the use of a
standardized tool such as the Visual Assessment Scale or Faces pain rating scale [30]. Despite
these limitations, these data do provide useful insights into the postoperative recoveries of
patients with PTA that could guide future investigation and practice.
5. Conclusions
The optimal management of PTA remains indeterminate. Previous studies have
reported good endocrine and CN outcomes in subclinical PTA patients who underwent
delayed surgery or medical management [31–35]. Furthermore, the definition of “early”
and “delayed” surgery in this condition is debated. In this single-institution retrospective
cohort study, the effects of surgical timing on headaches, vision, and extraocular movements
were analyzed using <4 days and >14 days as cutoffs for “early” and “delayed”, respectively.
This study includes a large cohort of patients that reflects the heterogeneity of this condition
observed in modern neurosurgical practice. All patients experienced severe headaches
and pituitary tumor hemorrhage/infarction, but many developed mild or no cranial nerve
dysfunction. While long-term outcomes did not vary by time to surgery in PTA patients
with minor visual deficits and/or deficits in ocular motility, surgery at all time points
was associated with prompt improvement in cranial nerve deficits. Headaches improved
significantly within 72 h in patients still experiencing severe headaches. The identification
of the factors that might predict rapid headache or cranial nerve response to surgical
decompression remains an important subject of future investigation.
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